FTC settlement with Cigna’s Express Scripts tightens rebate-linked PBM practices, adds disclosures, and raises pressure on CVS and OptumRx.
On Wednesday, February 4, 2026, the U.S. Federal Trade Commission said it reached a settlement with Express Scripts (owned by The Cigna Group) resolving the agency’s insulin-pricing case against that PBM, while litigation continues against CVS Caremark (CVS Health) and OptumRx (UnitedHealth Group). [1][2] The FTC framed the deal as an attempt to unwind what it alleges is a rebate-driven incentive loop: PBMs prefer higher list prices because bigger list prices can produce larger rebates and fees, even if net prices are negotiated down for some buyers. [1] As part of the settlement, Express Scripts agreed to restrictions around rebate-related practices the agency says can keep list prices elevated and raise out-of-pocket costs for certain patients. [1][2] Several operational commitments in the agreement are aimed at making PBM economics less opaque to the parties that actually pay the bills. Express Scripts will provide employers with annual disclosures about drug costs, and it also agreed to requirements related to working with local pharmacies. [1][2] The settlement includes a compliance overlay: an independent monitor will oversee Express Scripts for three years, and the agreement itself runs for 10 years—important because it converts previously announced “reforms” into enforceable obligations rather than optional policy. [1][2] One detail that underscores how much of PBM profitability sits in the plumbing: Express Scripts agreed to move Ascent Health Services, a Cigna-owned rebate aggregator, from Switzerland to the United States. [1][2] The FTC also estimated the package could reduce patient costs by up to $7 billion over 10 years (an agency estimate, not a booked corporate figure). [1][2] From a business lens, the point isn’t that PBMs disappear; it’s that regulators are trying to change what PBMs get paid for. If more compensation is forced into visible admin-style fees—and less into list-price-linked rebates/spreads—then the cash-flow profile of large PBM platforms could become more predictable but potentially less rich at the margins. That suggests more pressure on scale players to compete on service quality, formulary outcomes, and transparent pricing models rather than on financial engineering inside the supply chain. [1][2] This settlement also lands as the Department of Labor pushes a separate transparency agenda for employer plans, proposing rule changes that would require PBMs to disclose categories of compensation (including rebates and other payments) to plan fiduciaries. [3] SOURCES \[1\] Federal Trade Commission. “FTC Secures Landmark Settlement with Express Scripts to Lower Drug Costs for American Patients.” Press release. February 4, 2026. \[2\] Reuters. “Cigna settles FTC insulin case, aims to lower drug prices.” News article. February 4, 2026. Reuters. \[3\] U.S. Department of Labor, Employee Benefits Security Administration. “U.S. Department of Labor proposes historic pharmacy benefit manager fee disclosure rule.”...Value Investing Hub
Professional-grade stock analysis platform for value investors. Access DCF calculators, stock screeners, market insights, and educational resources.